Health status improvement with ferric carboxymaltose in heart failure with reduced ejection fraction and iron deficiency.

ABSTRACT:

Aim

Intravenous ferric carboxymaltose (FCM) has been shown to improve overall quality of life in iron-deficient heart failure with reduced ejection fraction (HFrEF) patients at a trial population level. This FAIR-HF and CONFIRM-HF pooled analysis explored the likelihood of individual improvement or deterioration in Kansas City Cardiomyopathy Questionnaire (KCCQ) domains with FCM versus placebo and evaluated the stability of this response over time.

Methods and results

Changes versus baseline in KCCQ overall summary score (OSS), clinical summary score (CSS) and total symptom score (TSS) were assessed at weeks 12 and 24 in FCM and placebo groups. Mean between-group differences were estimated and individual responder analyses and analyses of response stability were performed. O

SUBMITTER: Butler J 

PROVIDER: S-EPMC9313582 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature